BMJ  2005;331:1310-1316 (3 December), doi:10.1136/bmj.331.7528.1310

Primary care

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

¹ Division of Primary Care, University of Nottingham, Nottingham NG2 7RD, ² Division of Epidemiology and Public Health, University of Nottingham

Objective To determine the risk of an adverse upper gastrointestinal event in patients taking different cyclo-oxygenase-2 inhibitors compared with non-selective non-steroidal anti-inflammatory drugs.

Design Nested case-control study.

Setting 367 general practices contributing to the UK QRESEARCH database, spread throughout every strategic health authority and each health board in England, Wales, and Scotland.

Participants Patients aged 25 or more with a first ever diagnosis of an adverse upper gastrointestinal event (peptic ulcer or haematemesis) between 1 August 2000 and 31 July 2004 and up to 10 controls per case matched for age, sex, calendar time, and practice.

Main outcome measures Unadjusted and adjusted odds ratios for adverse upper gastrointestinal events associated with celecoxib, rofecoxib, ibuprofen, diclofenac, naproxen, other selective and non-selective non-steroidal anti-inflammatory drugs, and aspirin.

Results The incidence of adverse upper gastrointestinal events was 1.36 per 1000 person years (95% confidence interval 1.34 to 1.39). We identified 9407 incident cases and 88 867 matched controls. Increased risks of adverse gastrointestinal events were associated with current use of cyclo-oxygenase-2 inhibitors and with conventional non-steroidal anti-inflammatory drugs. Risks were reduced after adjustment for confounders but remained significantly increased for naproxen (adjusted odds ratio 2.12, 95% confidence interval 1.73 to 2.58), diclofenac (1.96, 1.78 to 2.15), and rofecoxib (1.56, 1.30 to 1.87) but not for current use of celecoxib (1.11, 0.87 to 1.41). We found clinically important interactions with current use of ulcer healing drugs that removed the increased risks for adverse gastrointestinal events for all groups of non-steroidal anti-inflammatory drugs except diclofenac, which still had an increased odds ratio (1.49, 1.26 to 1.76).

Conclusion No consistent evidence was found of enhanced safety against gastrointestinal events with any of the new cyclo-oxygenase-2 inhibitors compared with non-selective non-steroidal anti-inflammatory drugs. The use of ulcer healing drugs reduced the increased risk of adverse gastrointestinal outcomes with all groups of non-steroidal anti-inflammatory drugs, but for diclofenac the increased risk remained significant.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

Nicholas Latimer, Joanne Lord, Robert L Grant, Rachel O’Mahony, John Dickson, Philip G Conaghan on behalf of the National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group
BMJ 2009 339: b2538. [Abstract] [Full Text] [PDF]

Dyspepsia and Helicobacter pylori

Rupal Shah
BMJ 2007 334: 41-43. [Extract] [Full Text] [PDF]

Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency

Enrique J Sánchez-Delgado
BMJ 2006 332: 1451-1452. [Extract] [Full Text]

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Study conclusions do not reflect findings for celecoxib

Joe Feczko
BMJ 2005 331: 1473-1474. [Extract] [Full Text]

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: How strong is the evidence?

Bernard G Bannwarth
BMJ 2005 331: 1474. [Extract] [Full Text]

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Why were patients at major risk excluded?

Luca Puccetti
BMJ 2005 331: 1474. [Extract] [Full Text]

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option

Michael R Lewis and Diana Kay
BMJ 2005 331: 1474. [Extract] [Full Text]

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib?

Jonathan L Underhill
BMJ 2005 331: 1474-1475. [Extract] [Full Text]

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox and Carol Coupland
BMJ 2005 330: 1366. [Abstract] [Full Text] [PDF]

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review

Lee Hooper, Tamara J Brown, Rachel Elliott, Katherine Payne, Chris Roberts, and Deborah Symmons
BMJ 2004 329: 948. [Abstract] [Full Text] [PDF]

The electronic patient record in primary care—regression or progression? A cross sectional study

Julia Hippisley-Cox, Mike Pringle, Ruth Cater, Alison Wynn, Vicky Hammersley, Carol Coupland, Rhydian Hapgood, Peter Horsfield, Sheila Teasdale, and Christine Johnson
BMJ 2003 326: 1439-1443. [Abstract] [Full Text] [PDF]

Efficacy and safety of COX 2 inhibitors

Roger Jones
BMJ 2002 325: 607-608. [Extract] [Full Text] [PDF]

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Peter Jüni, Anne WS Rutjes, and Paul A Dieppe
BMJ 2002 324: 1287-1288. [Extract] [Full Text] [PDF]

Cross sectional survey of socioeconomic variations in severity and mechanism of childhood injuries in Trent 1992-7

Julia Hippisley-Cox, Lindsay Groom, Denise Kendrick, Carol Coupland, Elizabeth Webber, and Boki Savelyich
BMJ 2002 324: 1132. [Abstract] [Full Text] [PDF]

Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care

Julia Hippisley-Cox, Mike Pringle, Vicky Hammersley, Nicola Crown, Alison Wynn, Andy Meal, and Carol Coupland
BMJ 2001 323: 666-669. [Abstract] [Full Text] [PDF]

Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis

Hershel Jick, James A Kaye, Catherine Vasilakis-Scaramozza, and Susan S Jick
BMJ 2000 321: 1190-1195. [Abstract] [Full Text] [PDF]

Routine episiotomy should be abandoned

José M Belizán and Guillermo Carroli
BMJ 1998 317: 1389. [Extract] [Full Text]

Deprivation and emergency admissions for cancers of colorectum, lung, and breast in south east England: ecological study

Allyson M Pollock and Neil Vickers
BMJ 1998 317: 245-252. [Abstract] [Full Text] [PDF]

A memorable patient: Home glucose monitoring, who started it?

Clara Lowy
BMJ 1998 316: 1467. [Extract] [Full Text]

Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study

Oliver Blatchford, Lindsay A Davidson, William R Murray, Mary Blatchford, and Jill Pell
BMJ 1997 315: 510-514. [Abstract] [Full Text]

Variations in use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality

Nick Payne and Carol Saul
BMJ 1997 314: 257. [Abstract] [Full Text]

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

David Henry, Lynette L-Y Lim, Luis A Garcia Rodriguez, Susanne Perez Gutthann, Jeffrey L Carson, Marie Griffin, Ruth Savage, Richard Logan, Yola Moride, Chris Hawkey, Suzanne Hill, James T Fries, and James T Fries
BMJ 1996 312: 1563-1566. [Abstract] [Full Text]

Deprivation and cause specific morbidity: evidence from the Somerset and Avon survey of health

Jenny Eachus, Mark Williams, Philip Chan, George Davey Smith, Matthew Grainge, Jenny Donovan, and Stephen Frankel
BMJ 1996 312: 287-292. [Abstract] [Full Text]

Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom

T A Rockall, R F A Logan, H B Devlin, and T C Northfield
BMJ 1995 311: 222-226. [Abstract] [Full Text]

This article has been cited by other articles:

• Latimer, N., Lord, J., Grant, R. L, O'Mahony, R., Dickson, J., Conaghan, P. G, on behalf of the National Institute for Health and, (2009). Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 339: b2538-b2538 [Abstract] [Full text]  
• van der Linden, M W, van der Bij, S, Welsing, P, Kuipers, E J, Herings, R M C (2009). The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 68: 668-673 [Abstract] [Full text]  
• Wallace, J. L. (2008). Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?. Physiol. Rev. 88: 1547-1565 [Abstract] [Full text]  
• Hippisley-Cox, J., Vinogradova, Y., Coupland, C., Parker, C. (2007). Risk of Malignancy in Patients With Schizophrenia or Bipolar Disorder: Nested Case-Control Study. Arch Gen Psychiatry 64: 1368-1376 [Abstract] [Full text]  
• Smith, G., Hippisley-Cox, J., Harcourt, S., Heaps, M., Painter, M., Porter, A., Pringle, M. (2007). Developing a national primary care-based early warning system for health protection--a surveillance tool for the future? Analysis of routinely collected data. J Public Health (Oxf) 29: 75-82 [Abstract] [Full text]  
• Shah, R. (2007). Dyspepsia and Helicobacter pylori. BMJ 334: 41-43 [Full text]  
• Dalby, A. B., Frank, D. N., St. Amand, A. L., Bendele, A. M., Pace, N. R. (2006). Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota.. Appl. Environ. Microbiol. 72: 6707-6715 [Abstract] [Full text]  
• Helin-Salmivaara, A., Virtanen, A., Vesalainen, R., Gronroos, J. M., Klaukka, T., Idanpaan-Heikkila, J. E., Huupponen, R. (2006). NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27: 1657-1663 [Abstract] [Full text]  
• Sanchez-Delgado, E. J (2006). Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency.. BMJ 332: 1451-1452 [Full text]  
• Wallace, J. L. (2006). Commonality of Defensive Roles of COX-2 in the Lung and Gut. Am. J. Pathol. 168: 1060-1063 [Full text]  
• Bannwarth, B. G (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: How strong is the evidence?. BMJ 331: 1474-1474 [Full text]  
• Feczko, J. (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Study conclusions do not reflect findings for celecoxib. BMJ 331: 1473-1474 [Full text]  
• Puccetti, L. (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Why were patients at major risk excluded?. BMJ 331: 1474-1474 [Full text]  
• Lewis, M. R, Kay, D. (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option. BMJ 331: 1474-1474 [Full text]  
• Underhill, J. L (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib?. BMJ 331: 1474-1475 [Full text]  

Rapid Responses:

Read all Rapid Responses

Re: Hippisley-Cox et al, Risk of adverse GI outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Joe Feczko, MD
bmj.com, 3 Dec 2005 [Full text]

Risk of adverse GI outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

Bruce J Ella
bmj.com, 4 Dec 2005 [Full text]

Risk of adverse gastrointestinal outcome in patients taking COX-2 selective and non-selective non-steroidal anti-inflammatory drugs: how strong is the evidence?

Bernard G Bannwarth
bmj.com, 4 Dec 2005 [Full text]

Why did you exlude patients at major risk?

Luca Puccetti
bmj.com, 5 Dec 2005 [Full text]

NSAIDs, Cox-2 and Paracelsus. Risks and Benefits are determined by their Dosis and Potencies.

Prof. Enrique J. Sánchez-Delgado, MD
bmj.com, 5 Dec 2005 [Full text]

COX-2 inhibitors were thought of as a 'safe option'

Michael R Lewis, et al.
bmj.com, 6 Dec 2005 [Full text]

Remind us what the RCT evidence tells us about celecoxib again please?

Jonathan L Underhill
bmj.com, 6 Dec 2005 [Full text]

Adverse gastrointestinal outcomes and cyclo-oxygenase-2 inhibitors

Jean-louis MONTASTRUC, et al.
bmj.com, 9 Dec 2005 [Full text]

Study may show that COX-2-selective drugs in higher risk groups are as safe as NSAIDs in lower risk groups

Timothy D Warner, et al.
bmj.com, 9 Dec 2005 [Full text]

Poor headlines

Timothy B Webb
bmj.com, 14 Dec 2005 [Full text]

Online poll

Find out more on doc2doc >>